ライフサイエンスコーパス: antidiabetic agent

1 sis due to troglitazone (a thiazolidinedione antidiabetic agent).

2 y mass index, use of insulin, and other oral antidiabetic agents).

3 ium, which is a proposed insulin mimetic and antidiabetic agent.

4 tential role for EGCG, or derivatives, as an antidiabetic agent.

5 ntroquinonol indicate that it is a potential antidiabetic agent.

6 ent, whereas 7 (28%) of 25 controls required antidiabetic agents.

7 receptor pharmacology that may lead to novel antidiabetic agents.

8 long-acting insulin analogues and noninsulin antidiabetic agents.

9 ery and design of GK activators as potential antidiabetic agents.

10 ctivators represent a potential new class of antidiabetic agents.

11 hypoglycemia, and can be combined with other antidiabetic agents.

12 t passive GR antagonists may have utility as antidiabetic agents.

13 es-a group of potent PPAR gamma agonists and antidiabetic agents.

14 ailability of several unique classes of oral antidiabetic agents.

15 thiazolidinedione (TZD) and certain non-TZD antidiabetic agents.

16 lated compounds may represent a new class of antidiabetic agents.

17 Such chemical entities may prove useful as antidiabetic agents.

18 th other forms of therapy, for example, oral antidiabetic agents.

19 nimal models and have promise as potent oral antidiabetic agents.

20 iet and exercise therapy and the use of oral antidiabetic agents.

21 eed the in vitro activity of known synthetic antidiabetic agents.

22 A significant reduction in use of oral antidiabetic agents (80%) and insulin (79%) followed sur

23 ssant, antihyperlipidemic, antiulcerant, and antidiabetic agents--also demonstrated significant price

24 g, and prostate cancer and use of TZD, other antidiabetic agents, and insulin were identified.

25 With few exceptions, the available oral antidiabetic agents are equally effective at lowering gl

26 azone and pioglitazone), a new class of oral antidiabetic agents, are "insulin sensitizers" and exert

27 e, I discuss a rational basis for the use of antidiabetic agents as novel and potentially effective t

28 ngiotensin-converting enzyme inhibitor, oral antidiabetic agent, calcium, and vitamin D.

29 15d-PGJ2), or members of a new class of oral antidiabetic agents, e.g. BRL49653 and ciglitizone, has

30 t group) or short-acting insulin and/or oral antidiabetic agents for blood glucose >/=180-250 mg/dl (

31 enosine, glucose-insulin-potassium, statins, antidiabetic agents, FX06, iron chelation, and ranolazin

32 r-gamma (PPARgamma) agonists, a new class of antidiabetic agents, have been shown to possess antiinfl

33 Metabolic stress, as well as several antidiabetic agents, increases hepatic nucleotide monoph

34 y of such vanadium coordination complexes as antidiabetic agents is described.

35 mediate-acting insulin analogues) with other antidiabetic agents is urgently required to guide approp

36 PPARgamma agonists are antidiabetic agents known to suppress inflammatory macro

37 tion) in the presence of hyperglycemia, this antidiabetic agent may prove to have significant salutar

38 some of the beneficial effects of PPARgamma antidiabetic agents may result, at least in part, from t

39 Here, we show that both the antidiabetic agent metformin and insulin phosphorylate t

40 The complementary actions of the antidiabetic agents metformin hydrochloride and rosiglit

41 TNFRI combined with the antidiabetic agent, metformin, improved DBD beyond that

42 Troglitazone is an antidiabetic agent of the thiazolidinedione family.

43 those who were not under treatment with oral antidiabetic agents or insulin.

44 Compared with noninsulin antidiabetic agents, premixed insulin analogues were mor

45 ency in the thiazolidinedione (TZD) class of antidiabetic agents provided a dramatic increase in the

46 that incorporate a structural moiety of the antidiabetic agent succinobucol.

47 T2D patients are routinely treated with oral antidiabetic agents such as sulfonylureas or dipeptidyl

48 ly, the same pathway is activated by certain antidiabetic agents such as thiazolidinediones.

49 lar target of the thiazolidinedione class of antidiabetic agents suggested a key role for PPAR-gamma

50 Metformin is a first-line antidiabetic agent taken by 150 million people across th

51 Most antidiabetic agents target only 1 of several underlying

52 Thiazolidinediones are a new class of antidiabetic agent that improve insulin sensitivity and

53 The effects of metformin, an antidiabetic agent that improves insulin sensitivity, on

54 Troglitazone is an antidiabetic agent that improves the ability of adipocyt

55 We describe a class of antidiabetic agents that act as nonessential, mixed-type

56 ones (TZDs) such as BRL 49653 are a class of antidiabetic agents that are agonists for the peroxisome

57 Recent work has suggested that the antidiabetic agents, the thiazolidinediones (TZ), which

58 t, as well as members of a new class of oral antidiabetic agents, the thiazolidinediones, and a varie

59 s devoid of the side effects of the marketed antidiabetic agents thiazolidinediones and the dual agon

60 prostanoids and the synthetic high affinity antidiabetic agents thiazolidinediones.

61 Thus, PPARgamma activation in VSMCs, via the antidiabetic agent troglitazone or naturally occurring l

62 15-deoxy-delta12,14-prostaglandin J2 and the antidiabetic agent troglitazone.

63 and inhibition assays for canagliflozin, an antidiabetic agent verified its effective binding to bot

64 7, troglitazone, the first thiazolidinedione antidiabetic agent, was found to cause life-threatening

65 To study a new class of antidiabetic agents, we compared two small, nonpeptide m

66 In an effort to identify new antidiabetic agents, we have discovered a novel family o

67 Because PPARgamma is a target for antidiabetic agents, we investigated whether RXR ligands

68 ptidyl peptidase-4 inhibitor sitagliptin, an antidiabetic agent, which lowers blood glucose levels, a

69 NAADP is thus a potential antidiabetic agent with therapeutic relevance.